comparemela.com
Latest Breaking News On - Her2 positive early breast cancer - Page 1 : comparemela.com
Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.
Valencia
Carabobo
Venezuela
Spain
Antonio-llombart-cussac
University-hospital-arnau-de-vilanova
Oncology-service
Medical-oncology-service
Her2-positive-early-breast-cancer
Chemotherapy-free-regimen
Btrastuzumab
Pertuzumab
vimarsana © 2020. All Rights Reserved.